Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...